Anavex Life Sciences Corp (AVXL)

[Gator328]

Can someone please tell me when everyone here has had their fill? Is a pound of flesh from Dr. Missling not enough?

Nothing has changed. The company is flush with cash, and it has data it feels comfortable presenting to the FDA for a rare pediatric disease without any effective treatment options.

It’s biggest competitor in the Rett race also had positive data but there’s an asterisk of some uncomfortable side effects. I can see both company’s drugs being approved with MDs having the option to choose which to prescribe to patients.

The pediatric rare disease voucher can then be used to accelerate approval of A273 for another CNS disease, or it can be sold for about $1/share — think of it as a one-time dividend.

Dr. Missling is likely to be more careful with his communications now. We saw that today with the PR — meaningless to the share price but his best effort gesture to shareholders acknowledging he’s aware of our concerns.

I guess there is some cathartic effect in regurgitating how he screwed up but some people here are acting like he did something so nefarious that the FDA has no choice but to reject A273.

This simply isn’t the case. If nothing else, I could make the argument that no pre-revenue bio startup should have a MC of $1 billion and AVXL is now fairly valued, but that would just make the wolves here even hungrier for flesh — this time mine, not Dr Missling’s, so I’ll refrain.